We are pleased to announce that Tumor Discovery (TD, Online ISSN: 2810-9775, Publisher: AccScience Publishing) has been listed as a journal that follows the editorial recommendations of the International Committee of Medical Journal Editors (ICMJE) on October 27, 2023 (http://icmje.acponline.org/journals-following-the-icmje-recommendations/). The ICMJE is a small working group of general medical journal editors and representatives of selected related organizations working together to improve the quality of medical science and its reporting. In October 2023, under the application of TD, the ICMJE listed TD as a journal that follows the ICMJE's Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. This gave us great encouragement and confidence to develop TD as a premier, desirable, and transparent international platform for the dissemination of state-of-the-art fundamental and translational studies in tumor research. As an academic publishing platform, TD will continuously comply with the guidelines of Committee on Publication Ethics (COPE), World Association of Medical Editors (WAME), and ICMJE, and endeavor to publish more valuable and scientific research findings to promote scientific innovation.

On August 18, 2023, Tumor Discovery (TD, Online ISSN: 2810-9775) had been included in the esteemed database, Chemical Abstracts Service (CAS). This achievement stands as a significant milestone for our journal since its inception in 2022, signifying a remarkable acknowledgment of TD within the global academic community. The CAS database is founded in 1907 as a volunteer effort to organize published chemistry research, CAS officially became a self-supporting division of the American Chemical Society in 1956. CAS is widely acknowledged as the most comprehensive and authoritative source of chemical and scientific research. CAS provides access to over 150 million records from over 100 countries, including patents, scientific articles, and conference proceedings. Please click here to learn more about CAS: https://www.cas.org/. The editorial team at TD extends heartfelt gratitude to all esteemed members of the editorial board whose contributions have been instrumental in steering the journal's growth. We extend our appreciation to authors, reviewers, and readers alike for their unwavering support and profound engagement with the journal. Our pledge to provide a valuable platform for groundbreaking tumor research remains unwavering, underscored by our dedication to upholding the highest standards of publishing integrity. It is our aspiration to ascend as a premier international academic journal. TD will continue to uphold rigorous academic standards while publishing more high-quality articles, thereby improving our academic eminence and impact. These efforts are aimed at making greater contributions to academic research and technological innovation.